161 related articles for article (PubMed ID: 16101182)
21. A MUC1/IL-18 DNA vaccine induces anti-tumor immunity and increased survival in MUC1 transgenic mice.
Snyder LA; Goletz TJ; Gunn GR; Shi FF; Harris MC; Cochlin K; McCauley C; McCarthy SG; Branigan PJ; Knight DM
Vaccine; 2006 Apr; 24(16):3340-52. PubMed ID: 16472547
[TBL] [Abstract][Full Text] [Related]
22. Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer.
Barve M; Bender J; Senzer N; Cunningham C; Greco FA; McCune D; Steis R; Khong H; Richards D; Stephenson J; Ganesa P; Nemunaitis J; Ishioka G; Pappen B; Nemunaitis M; Morse M; Mills B; Maples PB; Sherman J; Nemunaitis JJ
J Clin Oncol; 2008 Sep; 26(27):4418-25. PubMed ID: 18802154
[TBL] [Abstract][Full Text] [Related]
23. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin.
von Mensdorff-Pouilly S; Verstraeten AA; Kenemans P; Snijdewint FG; Kok A; Van Kamp GJ; Paul MA; Van Diest PJ; Meijer S; Hilgers J
J Clin Oncol; 2000 Feb; 18(3):574-83. PubMed ID: 10653872
[TBL] [Abstract][Full Text] [Related]
24. Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma.
Yajima N; Yamanaka R; Mine T; Tsuchiya N; Homma J; Sano M; Kuramoto T; Obata Y; Komatsu N; Arima Y; Yamada A; Shigemori M; Itoh K; Tanaka R
Clin Cancer Res; 2005 Aug; 11(16):5900-11. PubMed ID: 16115932
[TBL] [Abstract][Full Text] [Related]
25. A synthetic vaccine consisting of a tumor-associated sialyl-T(N)-MUC1 tandem-repeat glycopeptide and tetanus toxoid: induction of a strong and highly selective immune response.
Kaiser A; Gaidzik N; Westerlind U; Kowalczyk D; Hobel A; Schmitt E; Kunz H
Angew Chem Int Ed Engl; 2009; 48(41):7551-5. PubMed ID: 19685547
[No Abstract] [Full Text] [Related]
26. Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma.
Loveland BE; Zhao A; White S; Gan H; Hamilton K; Xing PX; Pietersz GA; Apostolopoulos V; Vaughan H; Karanikas V; Kyriakou P; McKenzie IF; Mitchell PL
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):869-77. PubMed ID: 16467101
[TBL] [Abstract][Full Text] [Related]
27. [A phase I study of combination-therapy using personalized peptide vaccine and UFT/UZEL for advanced or recurrent colorectal cancer].
Hattori T; Okuno K; Yoshida K; Kokubu T; Mine T; Yamada R; Itoh K; Shiozaki H
Gan To Kagaku Ryoho; 2006 Nov; 33(12):1745-7. PubMed ID: 17212094
[TBL] [Abstract][Full Text] [Related]
28. Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma: evidence of systemic immune dysfunction.
; Celis E
Cancer; 2007 Jul; 110(1):203-14. PubMed ID: 17541944
[TBL] [Abstract][Full Text] [Related]
29. HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice.
Motomura Y; Ikuta Y; Kuronuma T; Komori H; Ito M; Tsuchihara M; Tsunoda Y; Shirakawa H; Baba H; Nishimura Y; Kinoshita T; Nakatsura T
Int J Oncol; 2008 May; 32(5):985-90. PubMed ID: 18425324
[TBL] [Abstract][Full Text] [Related]
30. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.
Santin AD; Bellone S; Palmieri M; Ravaggi A; Romani C; Tassi R; Roman JJ; Burnett A; Pecorelli S; Cannon MJ
Gynecol Oncol; 2006 Mar; 100(3):469-78. PubMed ID: 16249018
[TBL] [Abstract][Full Text] [Related]
31. A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer.
Rong Y; Qin X; Jin D; Lou W; Wu L; Wang D; Wu W; Ni X; Mao Z; Kuang T; Zang YQ; Qin X
Clin Exp Med; 2012 Sep; 12(3):173-80. PubMed ID: 21932124
[TBL] [Abstract][Full Text] [Related]
32. [Adoptive immunotherapy for pancreatic cancer, using MUC1 specific CTL].
Masaki Y; Oka M
Gan To Kagaku Ryoho; 1996 Oct; 23(12):1679-80. PubMed ID: 8886044
[TBL] [Abstract][Full Text] [Related]
33. Levels of circulating regulatory CD4+CD25+ T cells are decreased in breast cancer patients after vaccination with a HER2/neu peptide (E75) and GM-CSF vaccine.
Hueman MT; Stojadinovic A; Storrer CE; Foley RJ; Gurney JM; Shriver CD; Ponniah S; Peoples GE
Breast Cancer Res Treat; 2006 Jul; 98(1):17-29. PubMed ID: 16758122
[TBL] [Abstract][Full Text] [Related]
34. Tumor antigen-specific FOXP3+ CD4 T cells identified in human metastatic melanoma: peptide vaccination results in selective expansion of Th1-like counterparts.
Jandus C; Bioley G; Dojcinovic D; Derré L; Baitsch L; Wieckowski S; Rufer N; Kwok WW; Tiercy JM; Luescher IF; Speiser DE; Romero P
Cancer Res; 2009 Oct; 69(20):8085-93. PubMed ID: 19808957
[TBL] [Abstract][Full Text] [Related]
35. A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer.
Chianese-Bullock KA; Irvin WP; Petroni GR; Murphy C; Smolkin M; Olson WC; Coleman E; Boerner SA; Nail CJ; Neese PY; Yuan A; Hogan KT; Slingluff CL
J Immunother; 2008 May; 31(4):420-30. PubMed ID: 18391753
[TBL] [Abstract][Full Text] [Related]
36. Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
Holmes JP; Gates JD; Benavides LC; Hueman MT; Carmichael MG; Patil R; Craig D; Mittendorf EA; Stojadinovic A; Ponniah S; Peoples GE
Cancer; 2008 Oct; 113(7):1666-75. PubMed ID: 18726994
[TBL] [Abstract][Full Text] [Related]
37. Rethinking cancer vaccines to avoid T-cell traps.
Peoples GE
Immunotherapy; 2013 Jul; 5(7):665-8. PubMed ID: 23829613
[No Abstract] [Full Text] [Related]
38. Long-term outcome of immunotherapy for patients with refractory pancreatic cancer.
Nakamura M; Wada J; Suzuki H; Tanaka M; Katano M; Morisaki T
Anticancer Res; 2009 Mar; 29(3):831-6. PubMed ID: 19414316
[TBL] [Abstract][Full Text] [Related]
39. An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer.
Meyer RG; Korn S; Micke P; Becker K; Huber C; Wölfel T; Buhl R
Lung Cancer; 2007 Oct; 58(1):88-94. PubMed ID: 17599645
[TBL] [Abstract][Full Text] [Related]
40. Cellular and humoral immune responses to MUC1 mucin and tandem-repeat peptides in ovarian cancer patients and controls.
Snijdewint FG; von Mensdorff-Pouilly S; Karuntu-Wanamarta AH; Verstraeten AA; van Zanten-Przybysz I; Hummel P; Nijman HW; Kenemans P; Hilgers J
Cancer Immunol Immunother; 1999 Apr; 48(1):47-55. PubMed ID: 10235488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
